Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TulmiSTAR-01: Tulmimetostat and JSB462 in Progressive mCRPC
NCT07206056Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Primary completion
- Nov 2029
- Countries
- 14
01
Overview
A Phase 2 trial of tulmimetostat, luxdegalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Started Oct 2025; status: recruiting.
02
Drugs
tulmimetostatluxdegalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07206056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07206056.